Gold ticks up but remains pressured by Fed rate caution, easing trade fears
DUBLIN - Investment giant BlackRock, Inc. has disclosed a 6.81% stake in Avadel Pharmaceuticals plc, according to a regulatory filing published Wednesday.
The disclosure, made in accordance with Irish Takeover Panel rules, reveals BlackRock holds 6,641,787 ordinary shares in the pharmaceutical company as of October 28, 2025. The filing also shows the asset manager maintains short positions representing approximately 0.31% of Avadel’s shares.
Recent transaction details indicate BlackRock purchased 112,167 Avadel shares at prices around $18.59 per share while selling 197 shares. The filing also notes a stock loan transaction involving 75,700 shares and a transfer out of 10,036 shares.
The disclosure was required under Rule 8.3 of the Irish Takeover Panel Act, which mandates that entities holding interests of 1% or more in relevant securities must report their positions.
BlackRock’s stake in Avadel comes amid broader market interest in the pharmaceutical sector, though the filing does not indicate any specific takeover activity related to Avadel Pharmaceuticals.
The information was provided through a Form 8.3 filing, which is used for opening position disclosures under Irish takeover regulations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.